Nifty
Sensex
:
:
22957.10
75410.39
-10.55 (-0.05%)
-7.65 (-0.01%)

Pharmaceuticals & Drugs - Global

Rating :
67/99

BSE: 524804 | NSE: AUROPHARMA

1229.85
23-May-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1228.90
  •  1235.95
  •  1212.95
  •  1222.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  706992
  •  8674.42
  •  1235.95
  •  584.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 71,997.21
  • 25.99
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 71,170.98
  • 0.24%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.54%
  • 5.51%
  • FII
  • DII
  • Others
  • 18.01%
  • 22.86%
  • 1.25%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.87
  • 4.90
  • 0.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.71
  • -1.21
  • -6.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.09
  • -3.98
  • -29.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.78
  • 13.64
  • 13.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.76
  • 1.99
  • 1.69

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.11
  • 8.88
  • 8.68

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
7,351.78
6,407.13
14.74%
7,219.42
5,739.37
25.79%
6,850.52
6,235.92
9.86%
6,472.96
5,809.37
11.42%
Expenses
5,750.47
5,452.72
5.46%
5,845.98
4,948.58
18.13%
5,699.15
5,299.44
7.54%
5,470.78
4,834.97
13.15%
EBITDA
1,601.31
954.41
67.78%
1,373.44
790.79
73.68%
1,151.37
936.48
22.95%
1,002.18
974.40
2.85%
EBIDTM
21.78%
14.90%
19.02%
13.78%
16.81%
15.02%
15.48%
16.77%
Other Income
162.52
92.65
75.41%
186.98
57.19
226.95%
116.33
40.62
186.39%
134.91
48.88
176.00%
Interest
75.55
44.96
68.04%
68.18
25.29
169.59%
56.55
14.63
286.53%
55.60
9.21
503.69%
Depreciation
423.27
321.40
31.70%
417.50
298.10
40.05%
326.56
279.51
16.83%
345.57
253.57
36.28%
PBT
1,265.01
680.70
85.84%
1,074.74
524.59
104.87%
814.84
682.96
19.31%
735.92
597.74
23.12%
Tax
322.45
189.10
70.52%
323.70
112.99
186.49%
242.32
158.61
52.78%
224.15
17.49
1,181.59%
PAT
942.56
491.60
91.73%
751.04
411.60
82.47%
572.52
524.35
9.19%
511.77
580.25
-11.80%
PATM
12.82%
7.67%
10.40%
7.17%
8.36%
8.41%
7.91%
9.99%
EPS
15.98
8.38
90.69%
12.92
6.99
84.84%
9.74
8.88
9.68%
8.64
9.84
-12.20%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
27,894.68
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
Net Sales Growth
15.31%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
 
Cost Of Goods Sold
12,472.99
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
Gross Profit
15,421.69
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
GP Margin
55.29%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
Total Expenditure
22,766.38
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
Power & Fuel Cost
-
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
% Of Sales
-
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
Employee Cost
-
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
% Of Sales
-
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
Manufacturing Exp.
-
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
% Of Sales
-
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
General & Admin Exp.
-
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
% Of Sales
-
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
Selling & Distn. Exp.
-
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
% Of Sales
-
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
Miscellaneous Exp.
-
698.93
419.58
576.06
529.75
413.24
298.75
203.97
212.65
227.09
359.60
% Of Sales
-
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
EBITDA
5,128.30
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
EBITDA Margin
18.38%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
Other Income
600.74
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
Interest
255.88
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
Depreciation
1,512.90
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
PBT
3,890.51
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
Tax
1,112.62
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
Tax Rate
28.60%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
PAT
2,777.89
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
PAT before Minority Interest
2,780.85
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
Minority Interest
2.96
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
PAT Margin
9.96%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
PAT Growth
38.35%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
 
EPS
47.41
32.90
45.20
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
Total Reserves
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
Non-Current Liabilities
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
Secured Loans
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
Unsecured Loans
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
Long Term Provisions
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
Current Liabilities
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
Trade Payables
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
Other Current Liabilities
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
Short Term Borrowings
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
Short Term Provisions
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
126.60
Total Liabilities
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
Net Block
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
Gross Block
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
Accumulated Depreciation
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
Non Current Assets
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
Capital Work in Progress
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
Non Current Investment
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
Long Term Loans & Adv.
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
Other Non Current Assets
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
Current Assets
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
Current Investments
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
Inventories
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
Sundry Debtors
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
Cash & Bank
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
Other Current Assets
2,247.10
393.95
601.29
489.35
2,715.72
1,977.28
1,596.81
831.25
659.57
448.46
Short Term Loans & Adv.
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
Net Current Assets
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
Total Assets
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
PBT
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
Adjustment
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
Changes in Working Capital
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
Cash after chg. in Working capital
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
Net Fixed Assets
-503.76
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
Net Investments
-1,637.42
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
Others
-1,836.57
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
Cash from Financing Activity
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
Net Cash Inflow / Outflow
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
Opening Cash & Equivalents
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
Closing Cash & Equivalent
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
ROA
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
ROE
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
ROCE
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
Fixed Asset Turnover
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
Receivable days
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
Inventory Days
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
Payable days
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
Cash Conversion Cycle
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
Total Debt/Equity
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
Interest Cover
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94

News Update:


  • USFDA concludes inspection at Unit-VII of Aurobindo Pharma’s arm in Andhra Pradesh
    10th May 2024, 17:41 PM

    The inspection closed with 1 observation

    Read More
  • USFDA concludes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm
    5th Apr 2024, 17:15 PM

    The inspection closed with 3 observations

    Read More
  • Aurobindo Pharma gets final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray
    20th Mar 2024, 09:41 AM

    The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024

    Read More
  • Aurobindo Pharma’s arm restarts distribution of aseptic products manufactured at Unit III
    13th Mar 2024, 11:08 AM

    The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week

    Read More
  • Aurobindo Pharma gets final nod to manufacture, market Fingolimod Capsules, 0.5 mg
    2nd Mar 2024, 09:57 AM

    The product will be launched in March 2024

    Read More
  • USFDA concludes inspection at injectable facility of Aurobindo Pharma’s arm
    1st Mar 2024, 12:30 PM

    The inspection closed with 7 observations

    Read More
  • USFDA concludes inspection at synthetic peptide API facility of Aurobindo Pharma’s arm
    16th Feb 2024, 14:30 PM

    The inspection was concluded with zero observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.